TY - JOUR AU - Fried, M. W. AU - Shiffman, M. L. AU - Reddy, K. R. PY - 2002 DA - 2002// TI - Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection JO - N Engl J Med VL - 347 UR - https://doi.org/10.1056/NEJMoa020047 DO - 10.1056/NEJMoa020047 ID - Fried2002 ER - TY - JOUR AU - Durelli, L. AU - Verdun, E. AU - Barbero, P. PY - 2002 DA - 2002// TI - Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) JO - Lancet. VL - 359 UR - https://doi.org/10.1016/S0140-6736(02)08430-1 DO - 10.1016/S0140-6736(02)08430-1 ID - Durelli2002 ER - TY - JOUR AU - Cinatl, J. AU - Morgenstern, B. AU - Bauer, G. PY - 2003 DA - 2003// TI - Treatment of SARS with human interferons JO - Lancet. VL - 362 UR - https://doi.org/10.1016/S0140-6736(03)13973-6 DO - 10.1016/S0140-6736(03)13973-6 ID - Cinatl2003 ER - TY - JOUR AU - Chan, J. F. W. AU - Chan, K. H. AU - Kao, R. Y. T. PY - 2013 DA - 2013// TI - Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus JO - J Inf Secur VL - 67 ID - Chan2013 ER - TY - JOUR AU - Sheahan, T. P. AU - Sims, A. C. AU - Leist, S. R. PY - 2020 DA - 2020// TI - Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV JO - Nat Commun VL - 11 UR - https://doi.org/10.1038/s41467-019-13940-6 DO - 10.1038/s41467-019-13940-6 ID - Sheahan2020 ER - TY - JOUR AU - Chan, J. F. AU - Yao, Y. AU - Yeung, M. L. PY - 2015 DA - 2015// TI - Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset JO - J Infect Dis VL - 212 UR - https://doi.org/10.1093/infdis/jiv392 DO - 10.1093/infdis/jiv392 ID - Chan2015 ER - TY - JOUR AU - Blanco-Melo, D. AU - Nilsson-Payant, B. E. AU - Liu, W. C. PY - 2020 DA - 2020// TI - Imbalanced host response to SARS-CoV-2 drives development of COVID-19 JO - Cell VL - 181 UR - https://doi.org/10.1016/j.cell.2020.04.026 DO - 10.1016/j.cell.2020.04.026 ID - Blanco-Melo2020 ER - TY - JOUR AU - Vijay, R. AU - Perlman, S. PY - 2016 DA - 2016// TI - Middle East respiratory syndrome and severe acute respiratory syndrome JO - Curr Opin Virol VL - 16 UR - https://doi.org/10.1016/j.coviro.2016.01.011 DO - 10.1016/j.coviro.2016.01.011 ID - Vijay2016 ER - TY - STD TI - Clementi N, Ferrarese R, Criscuolo E, et al. Interferon-β 1a inhibits SARS-CoV-2 in vitro when administered after virus infection. J Infect Dis. 2020; jiaa350. [published online ahead of print, 2020 Jun 19]. ID - ref9 ER - TY - STD TI - “Solidarity” clinical trial for COVID-19 treatments [Internet]. [cited 2020 Apr 6]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. UR - https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments ID - ref10 ER - TY - JOUR AU - Hung, I. F. N. AU - Lung, K. C. AU - Tso, E. Y. K. PY - 2020 DA - 2020// TI - Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial JO - Lancet. VL - 395 UR - https://doi.org/10.1016/S0140-6736(20)31042-4 DO - 10.1016/S0140-6736(20)31042-4 ID - Hung2020 ER - TY - STD TI - Bosi C, Gori A, Raviglione M. Interferon beta in COVID-19: a landmark looming in the uncharted sea of COVID-19? J Public Health Emerg. 2020;4:8. ​https://doi.org/10.21037/jphe.2020.03.08. ID - ref12 ER - TY - STD TI - Ranieri VM, Pettilä V, Karvonen MK, et al. Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial. JAMA. 2020. https://doi.org/10.1001/jama.2019.22525 [published online ahead of print, 2020 Feb 17]. ID - ref13 ER - TY - JOUR AU - McGonagle, D. AU - O’Donnell, J. S. AU - Sharif, K. PY - 2020 DA - 2020// TI - Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia JO - Lancet Rheumatol VL - 2 UR - https://doi.org/10.1016/S2665-9913(20)30121-1 DO - 10.1016/S2665-9913(20)30121-1 ID - McGonagle2020 ER - TY - STD TI - Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020 [published online ahead of print, 2020 Apr 15]. ID - ref15 ER - TY - STD TI - Hippensteel JA, WB LR, Colbert JF, Langouët-Astrié CJ, Schmidt EP. Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol. [published online ahead of print, 2020 Jun 10]. ID - ref16 ER - TY - STD TI - Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19 - preliminary report. N Engl J Med. 2020; NEJMoa2007764. [published online ahead of print, 2020 May 22]. ID - ref17 ER - TY - JOUR AU - Geleris, J. AU - Sun, Y. AU - Platt, J. PY - 2020 DA - 2020// TI - Observational study of hydroxychloroquine in hospitalized patients with COVID-19 JO - N Engl J Med VL - 382 UR - https://doi.org/10.1056/NEJMoa2012410 DO - 10.1056/NEJMoa2012410 ID - Geleris2020 ER - TY - JOUR PY - 2001 DA - 2001// TI - PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS JO - Neurology. VL - 56 UR - https://doi.org/10.1212/WNL.56.12.1628 DO - 10.1212/WNL.56.12.1628 ID - ref19 ER - TY - JOUR AU - Ebers, G. C. AU - Rice, G. AU - Lesaux, J. PY - 1998 DA - 1998// TI - Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis JO - Lancet. VL - 352 UR - https://doi.org/10.1016/S0140-6736(98)03334-0 DO - 10.1016/S0140-6736(98)03334-0 ID - Ebers1998 ER - TY - STD TI - https://www.ema.europa.eu/en/documents/product-information/rebif-epar-product-information_en.pdf (Accessed July 1, 2020). UR - https://www.ema.europa.eu/en/documents/product-information/rebif-epar-product-information_en.pdf ID - ref21 ER - TY - JOUR AU - Lampasona, V. AU - Rio, J. AU - Franciotta, D. PY - 2003 DA - 2003// TI - Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients JO - Eur Cytokine Netw VL - 14 ID - Lampasona2003 ER - TY - JOUR AU - Polman, C. H. AU - Bertolotto, A. AU - Deisenhammer, F. PY - 2010 DA - 2010// TI - Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis JO - Lancet Neurol VL - 9 UR - https://doi.org/10.1016/S1474-4422(10)70103-4 DO - 10.1016/S1474-4422(10)70103-4 ID - Polman2010 ER -